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Abstract
Four HCC characteristics typically inform tumor behavior: maximum tumor size, number of nodules, portal vein
thrombosis and serum AFP level. The sum of these parameters was recently published as an HCC Aggressiveness
Index. We aimed to validate this index retrospectively in a larger and independent HCC cohort of 2706 Italian HCC
patients, and to evaluate a possible relationship between the index and liver function parameters. The scores in the
HCC Aggressiveness Index were again found to significantly relate to patient survival. Furthermore, in a multiple
logistic regression model of the Aggressiveness Index score categories, there were significant differences in several
liver parameter terciles amongst the score categories, suggesting a relationship of liver function to tumor
aggressiveness. It was concluded that a prognostically significant Tumor Aggressiveness Index was validated and
was found to be related to levels of some common liver function parameters.
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Abbreviations
HCC: Hepatocellular Carcinoma; AFP: Alpha-Fetoprotein; GGTP:
Gamma Glutamyl Transpeptidase; ALKP: Alkaline Phosphatase; AST:
Aspartate Aminotransferase; PVT: Portal Vein Thrombosis; MTD:
Maximum Tumor Diameter; CT: Computerized Axial Tomography
Scans.
Introduction
Four clinical HCC characteristics are generally considered in
assessing an individual patient’s tumor-related management and
prognosis. They are: maximum tumor diameter (MTD), number of
tumor nodules, portal vein invasion (PVT) and blood alpha-
fetoprotein (AFP) levels (as well as presence or absence of metastasis,
as with most solid tumor types). A recent ‘HCC Aggressiveness’
scoring system was recently described, which incorporated all 4 of
these parameters and related them to survival [1]. These 4 tumor
characteristics also were related to liver function parameters, given that
many tumors, including HCC, arise on the basis of a chronically
inflamed organ [2]. Furthermore, HCC patients with elevated bilirubin
levels have also been shown to have larger tumors and increased
incidence of PVT [3]. A recently validated index of systemic
inflammation, using the levels of only 2 liver-derived proteins, C-
reactive protein (CRP) and albumin has been shown in multiple
studies to be an independent prognosticator of survival [4-6]. The
platelet to lymphocyte ratio is another recently described, independent
inflammatory prognostic index for HCC [7]. In this paper, we
validated the new Aggressiveness Index on a separate and much larger
HCC patient cohort in relation to survival and we examined liver
function parameters in relation to the index. We found values for the
index also related significantly to survival, as well as to several liver
function parameters.
Methods
Patients and data collection
Data collection: We retrospectively analyzed prospectively-collected
data in the Italian Liver Cancer (ITA.LI.CA) study group database of
2706 HCC patients accrued till 2008 at 11 centers [3] who had full
baseline tumor parameter data, including CT scan information on
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maximum tumor diameter (MTD), number of tumor nodules and
presence of PVT and plasma AFP levels; blood counts (hemoglobin,
white cells, platelets, prothrombin time); routine blood liver function
tests, (total bilirubin, AST, ALKP, GGTP, albumin); demographics and
survival information. ITA.LI.CA database management conforms to
Italian legislation on privacy and this study conforms to the ethical
guidelines of the Declaration of Helsinki. Approval for this
retrospective study on de-identified patients was obtained by the
Institutional Review Board of participating centers.
Aggressiveness index: To construct an index that was the expression
of tumor aggressiveness, we have considered the following four
parameters: Maximum Tumor dimension (MTD), alpha-fetoprotein
(AFP), Portal Vein Thrombosis (PVT), and the number of tumor
nodules.
The Index score of Aggression was obtained as follows: MTD (in
tertiles): MTD < 4.5; 4.5 ≤ MTD ≤ 9.6; MTD > 9.6; scores 1, 2, 3
respectively. AFP (cut-off): AFP < 100; 100 ≤ AFP ≤ 1000; AFP > 1000
ng/ml; scores 1, 2, 3 respectively. PVT (No/Yes): PVT (No); PVT (Yes);
scores 1, 3 respectively. Tumor Nodule (number): Nodules ≤ 3;
Nodules > 3; scores 1, 3 respectively. Therefore the Aggressiveness




MTD (in terciles) (cm) <4.5 4.5 - 9.6 >9.6
AFP (cut-off) (ng/mL) <100 100 - 1000 >1000
PVT (No/Yes) No -- Yes
Tumor Nodules (number) ≤3 -- >3
MTD: Maximum Tumor Diameter, AFP: Alpha-fetoprotein, PVT: Portal Vein
Thrombosis. The Aggressiveness Index is the sum of the scores for MTD + AFP
+ PVT + # Nodules.
Table 1: Aggressiveness Index is the sum of parameter scores.
Thus: MTD (in tertiles): MTD < 4.5; 4.5 ≤ MTD ≤ 9.6; MTD > 9.6;
scores 1, 2, 3 respectively. AFP (cut-off): AFP < 100; 100 ≤ AFP ≤ 1000;
AFP > 1000 ng/ml; scores 1, 2, 3 respectively. PVT (No/Yes): PVT
(No); PVT (Yes); scores 1, 3 respectively. Tumor Nodule (number):
Nodules ≤ 3; Nodules > 3; scores 1, 3 respectively. The Aggressiveness
Index score was divided into three categories for Cox analysis (Table
2): a, score= 4; b, 4 < score ≤ 7; and c, score ≥ 8.
Statistical analysis: Mean and SD for continuous variables were used
as indices of centrality and dispersion of the distribution. For non-
normally distributed values we was necessary used a non-parametric
methods, the Wilcoxon rank-sum (Mann-Whitney) test, for
continuous variables, to test the comparisons between the
Aggressiveness Index categories of liver function parameters.
The Cox proportional hazards model was applied to evaluate the
predictive factors as categories of Aggressiveness Index score
associated with overall survival. The results were presented as Hazard
Ratio (HR) with 95% C.I. Unconditional multiple logistic regression
model was used to evaluate the Odds-Ratio of the Aggressiveness
Index score (≥8) on the terciles of each serum variable, Gamma
Glutamyl Transpeptidase (GGTP), Alkaline Phosphatase (ALKP), and
Aspartate Aminotransferase (AST), total bilirubin and platelets as
terciles; while albumin levels were dichotomized. All variables were
included together in the model. The results were presented as Odds-
Ratio (OR) with 95% C.I.
In all models, Cox regression and Logistic regression, the HR and
the OR respectively, represent the risk for one-unit variation of the
predictor variable considered as dummy variables. Patient survival
between the three categories of Aggressiveness Index score was
estimated with the Kaplan-Meier method and comparison of survival
was made with the Breslow (generalized Wilcoxon) test. The Breslow
test was used, as opposed to the log rank test, due to the large
proportion of patients who died early.
When testing the hypothesis of significant association, p-value was
< 0.05, two tailed for all analyses. Statistical analysis was performed
with State Corp 2007 State Statistical Software: release 10. College
Station, TX: StataCorp LP.
Result
Aggressiveness index and survival
An Aggressiveness Index was constructed as described previously
[1] and as shown in Table 1, was the sum of the scores for MTD, tumor
multimodality, PVT and AFP values. Using the designated cutoffs for
point systems, patients were divided into 3 groups a, b and c (Table 1),
using a score from 4 (lowest score, with 1 point per parameter) to 12
(highest score, with 3 points per parameter). The Kaplan-Meier
survival graph (Figure 1).
Figure 1: Kaplan-Meier Survival plots between categories of
Aggressiveness Index, in patients having bilirubin < 1.5 mg/dL.
Showed statistically significant differences in survival between the 3
groups. The percent survival probabilities for the 3 groups, a, b and c
were: 94%, 77% and 39% at 1 year, and 81%, 57% and 14% at 2 years,
and 67%, 39% and 7% at 3 years, for the 3 groups, from the lowest to
the highest scores.
A Cox proportional hazard model for death was then calculated
(Table 2), with score (a) being the reference category. The hazard ratios
(HRs) for groups a, b and c were: 1, 1.94 and 6.64, respectively, with p-
values of <0.001 for a vs. b, a vs. c and b vs. c.
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HR* se(HR) p 95% C.I. Comparisons of HRs p
Aggressiveness Index
Score = 4 [Ref. category] (a) 1 -- -- -- (a) vs (b) <0.001
4 < Score ≤ 8 (b) 1.94 0.14 <0.001 1.68 to 2.25 (a) vs (c) <0.001
8 < Score ≤ 12 (c) 6.64 1.27 <0.001 4.56 to 9.66 (b) vs (c) <0.001
Table 2: Cox proportional hazard model in HCC patients for death, on Aggressiveness Index Score categories in the total cohort.
Aggressiveness index and liver function parameters
The relationship between the Aggressiveness Index and liver
function parameters was then examined. Firstly, the mean liver
function parameters for the worst Index group (score ≥ 8) were
compared to the other 2 groups combined (score < 8) (Table 3).
Aggressiveness Index Score
(M ± SD) Score < 8 Score ≥ 8 p°
GGTP (IU/mL) 77.0 ± 103.3 96.7 ± 87.5 <0.0001
ALKP (IU/mL) 285.2 ± 1266.4 312.8 ± 656.0 <0.0001
AST (IU/L) 44.4 ± 48.1 56.3 ± 56.5 0.0005
Total Bilirubin (mg/dL) 1.7 ± 2.1 2.9 ± 4.2 <0.0001
Albumin (g/dL) 3.6 ± 0.63 3.2 ± 0.62 <0.0001
Platelets (x109/L) 116.0 ± 62.0 136.4 ± 81.9 0.0018
° Wilcoxon rank-sum (Mann-Whitney) test. Abbreviations: Plt, Platelet count; Hb, Haemoglobin; GGTP, Gamma glutamyl transpeptidae; ALKP, Alkaline phosphatase;
AST, Aspartate Aminotransaminase.
Table 3: Comparisons in HCC patients between Aggressiveness Index Score of Platelets, GGTP, ALKP, AST, Total Bilirubin and Albumin, in the
total cohort.
The mean values were all statistically higher for group the worst
Index group than for the lower group in the Index, with respect to
GGTP, ALKP, AST, total bilirubin, and platelets, only albumin had a
slightly lower value (an index of liver fibrosis) [8,9]. Secondly, a
multiple logistic regression model was calculated for the
Aggressiveness Index on the liver parameters, each divided into terciles
(Table 4).
 OR se(OR) p 95% C.I. p§
GGTP (IU/mL)     0.001
≤33.0 [Ref. category] 1     
>33.0/ ≤73.2 1.98 0.44 0.002 1.29 to 3.06  
>73.2 2.09 0.47 0.001 1.34 to 3.26  
ALKP (IU/mL)     0.07
≤186 [Ref. category] 1     
>186/ ≤232 0.84 0.18 0.42 0.54 to 1.29  
>232 1.41 0.28 0.08 0.96 to 2.08  
AST (IU/L)     0.05
≤26.0 [Ref. category] 1     
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>26.0/ ≤44.8 1.07 0.23 0.77 0.70 to 1.63  
>44.8 1.46 0.3 0.06 0.98 to 2.19  
Total Bilirubin (mg/dL)     <0.001
<1.0 [Ref. category] 1     
≥1.0/ ≤2.0 1.52 0.33 0.06 0.99 to 2.33  
>2.0 2.36 0.58 0.001 1.45 to 3.82  
Albumin (g/dL)     <0.001
<3.5 [Ref. category] 1     
≥3.5 0.46 0.08 <0.001 0.32 to 0.65  
Platelets (×109/L)     0.001
<100 [Ref. category] 1     
≥100/ ≤300 1.55 0.27 0.01 1.11 to 2.18  
>300 4.98 2.3 0.001 2.01 to 12.30  
§ p-value for trend. Abbreviations: OR: Odds-Ratio, GGTP: Gamma Glutamyl Transpeptidase, ALKP: Alkaline Phosphatase, AST: Aspartate Aminotransferase.
Table 4: Multiple logistic regression model of Aggressiveness Index score (≤7/ ≥8), on variables as terciles included together in the model in the
total cohort.
The highest Odds Ratios (ORs) were for GGTP, total bilirubin and
platelets, and each parameter had a significant p-value for trend of the
terciles. Albumin was dichotomized at <3.5 or >3.5 g/dl, as in the
Glasgow score and showed a significant protective effect.
Discussion
Tumor factors and liver factors have separately and together been
acknowledged to be important for HCC prognosis and management
decisions. As a result, elements of both sets of factors are included in
most HCC classification and prognostication systems [10] with
increasing refinements [11]. The underlying liver has been increasingly
understood as a complex dynamic of cells, tissues, inflammatory
cytokines and growth factors [12-18]. This has been most extensively
studied with respect to the neo vascular endothelial cells that form the
blood vessels that are needed to support the growing tumor mass, and
are an important target for various multikinase inhibitors, which are
used in cancer therapy. In addition, several cell types in the tumor
microenvironment and their secreted products, are involved in the
immune and inflammatory pathways [13,14]. Two general categories
of inflammation can be discerned in cancer in general, including HCC.
They are: (a), local, micro environmental inflammation [17,18], such as
that associated with chronic hepatitis [19]; and (b), systemic
inflammation, as measured by blood C-reactive protein and albumin
levels in the Glasgow and similar inflammation-based prognostic
scoring systems [4-6,20]. Some micro environmental cell types have
multiple functions, such as platelets, which are involved in blood
coagulation, metastasis [21], and hepatitis B immune modulation [22],
HCC cell growth and migration [23] and the production of HCC
growth stimulants [24].
Recently, there has been a paradigm shift, as it has become apparent
that the liver microenvironment and liver disease factors are not only
independent negative prognostic factors for HCC survival, but may
actually be involved in HCC biology. It has long been accepted that
growing HCC tumor masses can destroy or replay liver parenchyma
and thus enhance liver damage. There is now evidence that the
converse is also likely true and that liver micro environmental factors
may influence HCC growth and invasion [12-19]. Molecular signatures
of the underlying liver in HCC patients provide support for this idea
[25-27], as well as recently reported clinical associations of changes in
liver function with HCC biology [3].
The experiments reported here had 2 goals. Firstly, to confirm using
a different and larger HCC cohort, that the recently-described HCC
Aggressiveness Index could be reproduced, with significant survival
differences for patients in its 3 score groups of a, b and c (Figure 1). To
our knowledge, there has not previously been an HCC index that takes
into account all 4 of the commonly-used modalities of HCC human
biology, namely tumor size (MTD), tumor multifocality, and portal
venous invasion by tumor (PVT) and blood AFP levels. It was expected
that the worst category group (highest points) would have the worst
survival, and vice versa. We found a decrease in survival with increase
in score for each of years 1, 2 and 3 (Figure 1, Kaplan-Meier graph and
its associated table). The Cox regression model (Table 2) showed an
increasing Hazard Ratio (HR) for death in groups a, b and c, of 1
(reference), 1.94 and 6.64, respectively. The second goal was to
examine any possible relationship between the Aggressiveness Index
groups and parameters of liver function (Table 3 and multiple logistic
regressions in Table 4). We found (Table 3) significantly higher liver
parameter values for Aggressiveness group c (Score > 8) compared to
Aggressiveness groups a plus b (Score < 8), with respect to GGTP,
ALKP, AST and total bilirubin, as well as for platelets (a surrogate for
liver cirrhosis [8,9]). The converse was found for albumin, as expected
from its published protective association for survival [4,5]. A multiple
logistic regression model for these same parameters as terciles, on the
Aggressiveness Index score (Table 4), showed the highest Odds Ratios
(OR) were for GGTP, total bilirubin and platelet counts (highest, OR).
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The results presented here show an association between liver
function parameters and increasing tumor aggressiveness, but do not
show a causal relationship. Nevertheless, the association is quite
remarkable. Given the newly available and effective therapies for
hepatitis B and C (and possibly also anti-inflammatory agent, such as
aspirin, NSAIDS, Cox inhibitors, in patients without bleeding
disorder), it may be that their use in suppressing hepatic inflammation
and/or improving liver function in HCC patients with inflamed livers,
offer the possibility of decreasing HCC aggressiveness through
improvement of the underlying liver function [28-32]. What might be
the mechanisms by which liver function parameters could influence
HCC aggressiveness Two possible general explanations might be
considered. A first is that the liver function parameters are only passive
measures that reflect the underlying hepato carcinogenic processes of
cirrhosis. A second possibility is that the liver parameters actually have
HCC-modifying functions. Thus, albumin has been shown to subdue
HCC cell growth [33]; HCC-specific GGT isoforms are membrane
glycoproteins that catalyze the first enzymatic step in the metabolism
of glutathione and is important in maintaining intracellular cysteine
and glutathione levels [34-36], ALKP might modulate cancer drug
resistance [37] as might bilirubin [38,39]. Furthermore, platelet factors
have HCC-stimulatory properties [24].
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